Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Is Bristol-Myers Squibb the Most Undervalued Biotech Company?

March 20, 2025
Recently, the European Commission (EC) has given its approval to Breyanzi, a novel treatment developed by Bristol-Myers Squibb (BMS) for Non-Hodgkin's Lymphoma (NHL). This represents a significant milestone for the company, as it expands its portfolio in the oncology space.

Breyanzi, a CAR-T cell therapy, has shown promising results in clinical trials, demonstrating its potential to improve patient outcomes in NHL treatment. The EC's nod further validates BMS's commitment to addressing unmet medical needs and providing innovative solutions for patients.

Despite this positive news, BMS shares experienced a dip in the stock market on Friday. However, it is important not to jump to conclusions based on short-term fluctuations. Investors are advised to seek professional advice from experts at Stocks Prognosis to make informed decisions about the future movement of BMS stocks.

As a leading biotech company, BMS is dedicated to transforming patients' lives through science. With a robust pipeline and ongoing research efforts, the company continues to make significant contributions to the healthcare industry. For those interested in this sector, BMS presents a potential buying opportunity, considering its undervalued position.

Stay updated with the latest developments in the biotech industry, including Bristol-Myers Squibb, to make informed investment decisions. Consult experts at Stocks Prognosis to get professional insights and forecasts on the movement of BMS stocks.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved  ~1 min.

On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....


BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit  ~1 min.

QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....


BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....


BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....


BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....


GSKJanuary 25, 2025Is GSK plc GSK an Undervalued Defensive Stock for 2025?  ~2 min.

GSK plc (NYSE: GSK) has been gaining attention as a potential undervalued defensive stock for investors looking towards 2025....


BIIBDecember 31, 2024Biogen Inc. BIIB: Revolutionizing Healthcare with Breakthrough Research  ~2 min.

Biogen Inc. (BIIB) has emerged as a standout player in the healthcare industry, continuously pushing the boundaries of medical research and development....


AMGNFebruary 4, 2025Amgen Inc. AMGN Reports Next Week: Wall Street Expects Earnings Growth  ~2 min.

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, is set to report its latest earnings next week, and Wall Street is expecting strong growth....


BIIBJanuary 2, 2025Biogen Inc. Shows Promise as a Strong Value Stock for Long-Term Investments  ~2 min.

Biogen Inc. (NASDAQ:BIIB) has emerged as a top value stock for investors looking for long-term growth opportunities....


BIIBJanuary 2, 2025Biogen Inc.: Revolutionizing Healthcare with Innovative Biotechnology  ~2 min.

Biogen Inc. (BIIB) is setting new standards in the healthcare industry with its groundbreaking biotechnology solutions....